AI Article Synopsis
Article Abstract
Background: In metastatic colorectal cancer (mCRC), the genetic structure and cell metabolism of the primary tumor lesion might be different from metastatic lesions. It is thought that cell-level glucose metabolism may differ due to the difference in RAS wild and mutant mCRC patients' prognosis. In this study, we aimed to compare 2-deoxy-2-[fluorine-18]-fluoro-D-glucose Positron Emission Tomography (18F-FDG PET/CT) uptake levels for KRAS mutation status and primary-metastatic tumor localization.
Methods: Our study is a retrospective cohort analysis that included RAS mutation status study and staging-oriented 18F-FDG PET/CT conducted on mCRC patients.
Results: There was no significant relationship between metastasis and primary tumor maximum Standardized uptake value (SUVmax) values according to the KRAS mutational status (P > 0.05). Patients with liver metastasis along with mutant BRAF mutation status had significantly higher SUVmax values in PET-CT scans (P = 0.04). There was a negative correlation between SUVmax values of lung metastases and overall survival (r = -0.35, P = 0.04). Patients with high carcinoembryonic antigen (CEA) levels had significantly higher SUVmax values of lung metastasis than patients with normal CEA levels (P = 0.009). Patients with high CA19-9 levels had significantly higher SUVmax values of liver, peritoneal, and bone metastasis than patients with normal CA19-9 levels (P = 0.002, P = 0.001, P = 0.004, respectively). There was no significant correlation between SUVmax values of metastasis and Lactate dehydrogenase (LDH) values. Liver metastasis of right-sided mCRCs had significantly higher SUVmax values (P = 0.03).
Conclusion: We could not demonstrate a significant association between KRAS mutation and SUVmax values of PET scan in primary or metastatic tumor sites in advanced CRC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4103/ijc.IJC_4_20 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Predictive value of 18F-FDG PET/CT metabolic parameters for lymph node metastasis of non-small cell lung cancer.
Biomark Med
December 2024
Nuclear Medicine, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China.
Background: Lymph node metastasis is closely associated with the prognosis of patients with non-small cell lung cancer (NSCLC). This study aimed to evaluate the role of preoperative 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) parameters in mediastinal lymph node metastasis in NSCLC.
Methods: One hundred patients with NSCLC who underwent surgery, systematic lymph node dissection, who had undergone 18FFDG PET/CT for initial staging were divided into two groups: lymph node metastasis and non-metastasis.
Ga-pentixafor PET/CT Is a Supplementary Method for Primary Aldosteronism Subtyping Compared with Adrenal Vein Sampling.
Mol Imaging Biol
December 2024
Department of Nuclearuclear Medicine, Peking University First Hospital, Beijing, China.
Purpose: To investigate the diagnostic efficacy of Ga-pentixafor positron emission tomography/computed tomography (PET/CT) in primary aldosteronism (PA) subtyping and lateralization of aldosterone secretion in PA patients.
Procedures: 37 patients who were diagnosed with PA, were prospectively enrolled in the study, and underwent adrenal vein sampling (AVS) after Ga-pentixafor PET/CT was conducted. Lateralization index (LI), defined as aldosterone/cortisol ratio in the dominant side to the contralateral adrenal vein when bilateral adrenal vein catheterization succeeded, and the aldosterone/cortisol ratio in the left adrenal vein to IVC (LAV/IVC) when the catheterization of right adrenal vein failed, were applied to determine lateralization side.
Correlation between [18F]-FDG PET/CT findings and pathological subtypes of lung adenocarcinoma presenting as ground-glass opacity.
Rev Esp Med Nucl Imagen Mol (Engl Ed)
December 2024
Department of Nuclear Medicine, Jinling Hospital, Medical school of NanjingUniversity, Nanjing, Jiangsu Province, 210002, China.
Objective: The aim of this study is to analyze the correlation between [18F]-FDG PET/CT (positron emission tomography/computed tomography) findings and pathological subtypes of lung adenocarcinoma with ground-glass opacity (GGO).
Materials And Methods: 88 patients were included in this study, which underwent [18F]-FDG PET/CT and were finally diagnosed with lung adenocarcinoma. A total of 90 GGO lesions were analyzed.
The Relationship Between HER2 Status Acquired From Pathological Data and Metabolic Parameters From Pre-treatment [F]FDG PET/CT in Gastric Adenocarcinomas.
Rev Esp Med Nucl Imagen Mol (Engl Ed)
December 2024
Department of Medical Oncology, Prof. Dr. Cemil Taşcıoğlu City Hospital, Istanbul, Turkey.
Objective: Overexpression of Human Epidermal Growth Factor Receptor 2 (HER2) is thought to be more aggressive in gastric cancer. This study aimed to evaluate the predictability of HER2 status and other prognostic pathologic parameters using [F]FDG PET/CT and to investigate its impact on survival.
Methods: Pretreatment metabolic parameters measured by [F]FDG PET/CT as a prognostic factor were retrospectively evaluated in 117 HER2-analysed patients.
Prognostic value of metabolic tumor volume on [F]FDG PET/CT in addition to the TNM classification system of locally advanced non-small cell lung cancer.
Cancer Imaging
December 2024
Department of Translational Imaging in Oncology, National Center for Tumor Diseases (NCT/UCC) Dresden, Medical Faculty and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Fetscherstraße 74, Dresden, 01307, Germany.
Purpose: Staging of non-small cell lung cancer (NSCLC) is commonly based on [F]FDG PET/CT, in particular to exclude distant metastases and guide local therapy approaches like resection and radiotherapy. Although it is hoped that PET/CT will increase the value of primary staging compared to conventional imaging, it is generally limited to the characterization of TNM. The first aim of this study was to evaluate the PET parameter metabolic tumor volume (MTV) above liver background uptake as a prognostic marker in lung cancer.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!